Impax's Appeal Too Late In Amrix Case, Fed. Circ. Says

Law360, New York (February 14, 2013, 6:45 PM EST) -- The Federal Circuit has blocked Impax Laboratories Inc. from selling a generic version of Cephalon Inc.’s muscle relaxant Amrix, finding that Impax waited too long to appeal the sales ban put in place by a lower court, according to an opinion unsealed Thursday.

A three-judge panel found that despite Impax’s assertions to the contrary, the drugmaker is subject to a May 2011 preliminary injunction blocking all generic versions of Amrix from entering the market, and should have brought its appeal within 30 days of the ruling for...
To view the full article, register now.